NCT02650895View on ClinicalTrials.gov

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 2, 2014

Primary Completion Date

January 15, 2015

Study Completion Date

January 15, 2015

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

Efprezimod alfa

Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain

DRUG

Saline

0.9% sodium chloride

Trial Locations (1)

45227

Medpace Clinical Pharmacology Unit (CPU), Cincinnati

All Listed Sponsors

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02650895 - Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001) | Biotech Hunter | Biotech Hunter